KPIs & Operating Metrics(New)
Growth Metrics

Astrazeneca (AZN) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Astrazeneca (AZN) over the last 17 years, with Q4 2025 value amounting to $85.4 billion.

  • Astrazeneca's Non-Current Assets rose 913.33% to $85.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $85.4 billion, marking a year-over-year increase of 913.33%. This contributed to the annual value of $85.4 billion for FY2025, which is 913.33% up from last year.
  • Per Astrazeneca's latest filing, its Non-Current Assets stood at $85.4 billion for Q4 2025, which was up 913.33% from $84.5 billion recorded in Q3 2025.
  • Astrazeneca's 5-year Non-Current Assets high stood at $85.4 billion for Q4 2025, and its period low was $46.2 billion during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $77.2 billion (2022), whereas its average is $75.0 billion.
  • Its Non-Current Assets has fluctuated over the past 5 years, first surged by 11860.02% in 2021, then crashed by 815.72% in 2022.
  • Over the past 5 years, Astrazeneca's Non-Current Assets (Quarter) stood at $79.1 billion in 2021, then dropped by 6.61% to $73.9 billion in 2022, then grew by 2.94% to $76.1 billion in 2023, then grew by 2.82% to $78.2 billion in 2024, then increased by 9.13% to $85.4 billion in 2025.
  • Its Non-Current Assets stands at $85.4 billion for Q4 2025, versus $84.5 billion for Q3 2025 and $83.5 billion for Q2 2025.